右旋糖酐铁联合促红细胞生成素对妊娠期缺铁性贫血患者网织红细胞、铁调素-25水平的影响

摘要
图/表
参考文献(17)
相关文章 (15)

全文: PDF (630 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨右旋糖酐铁联合促红细胞生成素（EPO）的应用对妊娠期缺铁性贫血患者网织红细胞（RET）、铁调素-25 水平的影响。方法选取2021年7月至12月上饶市人民医院收治的80 例妊娠期缺铁性贫血孕妇作为研究对象，采用随机数字表法将其分为观察组（40 例）和对照组（40 例）。对照组患者采取EPO 治疗，观察组患者则在对照组基础上增加右旋糖酐铁进行治疗。观察和比较两组患者的贫血相关指标，包括血红蛋白（Hb）、红细胞平均体积（MCV）和EPO 水平；比较两组患者的血清铁有关指标，包括铁蛋白（SF）水平、铁调素-25、膜转运蛋白1（FPN1）、铁幼素（HJV）水平及可溶性转铁蛋白受体（sTfR）水平；比较两组患者的血液学指标，包括RET 计数、RET 比率（MFR）、未成熟RET 比率（IRF）、低荧光RET 比率（LFR）、血红蛋白含量（RET-He）。结果治疗前，两组患者的Hb、MCV、EPO、SF、sTfR、铁调素-25、FPN1、HJV、RET、MFR、IRF、LFR、RET-He 水平比较，差异无统计学意义（P>0.05）；观察组患者治疗1 个月后的Hb、MCV 水平高于对照组，EPO 水平低于对照组，差异有统计学意义（P<0.05）；观察组患者治疗1 个月后的SF、铁调素-25、HJV 水平高于对照组，sTfR、FPN1 水平低于对照组，差异有统计学意义（P<0.05）；观察组患者治疗1 个月后的RET、MFR、IRF 水平低于对照组，LFR、RET-He 水平高于对照组，差异有统计学意义（P<0.05）。结论应用右旋糖酐铁联合EPO 治疗妊娠期缺铁性贫血患者，可抑制患者RET、铁调素-25 水平的异常表达，能够有效改善患者的贫血状况。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	钟丽
	张戈

关键词 ：右旋糖酐铁, 促红细胞生成素, 妊娠期, 缺铁性贫血, 网织红细胞, 铁调素-25

Abstract：Objective To explore the application effect of Iron Dextran combined with erythropoietin (EPO) on the levels of reticulocyte (RET) and hepcidin-25 in patients with iron deficiency anemia during pregnancy. Methods A total of 80 pregnant women with iron deficiency anemia during pregnancy who were treated in Shangrao People′s Hospital between July and December 2021 were selected as the research subjects, and they were divided into observation group(40 cases) and control group (40 cases) by random number table method. The patients in the control group were treated with EPO, while the patients in the observation group were additionally given Iron Dextran on the basis of the control group. The anemia-related indicators, including hemoglobin (Hb), mean corpuscular volume (MCV) and EPO levels were observed and compared between the two groups. Serum iron related indexes, including ferritin (SF) level, hepcidin-25, membrane transporter 1 (FPN1), hemojuvelin (HJV) level and soluble transferrin receptor (sTfR) level were compared between the two groups. Hematological indexes, including RET count, mature RET ratio (MFR), immature RET fraction (IRF), low fluorescence RET ratio (LFR) and hemoglobin content (RET-He) were compared between the two groups. Results Before treatment, there were no significant differences in the levels of Hb, MCV, EPO, SF, sTfR,hepcidin-25, FPN1, HJV, RET, MFR, IRF, LFR and RET-He between the two groups (P>0.05). After 1 month of treatment, the levels of Hb and MCV in the observation group were higher than those in the control group, and the level of EPO in the observation group was lower than that in the control group, and the differences were statistically significant(P<0.05). After 1 month of treatment, the levels of SF, hepcidin-25 and HJV in the observation group were higher than those in the control group, and the levels of sTfR and FPN1 in the observation group were lower than those in the control group, and the differences were statistically significant (P<0.05). After 1 month of treatment, the levels of RET,MFR and IRF in the observation group were lower than those in the control group, and the levels of LFR and RET-He in the observation group were higher than those in the control group, and the differences were statistically significant (P<0.05). Conclusion The application of Iron Dextran combined with EPO in the treatment of patients with iron deficiency anemia during pregnancy can inhibit the abnormal expression of RET and hepcidin-25 levels, which can effectively improve the anemia status of patients.

Key words： Iron Dextran Erythropoietin Pregnancy Iron deficiency anemia Reticulocyte Hepcidin-25

基金资助:江西省卫生健康委科技计划项目（202212765）

作者简介: 钟丽（1986-），女，汉族，湖南常德人，硕士，研究方向：妊娠期糖尿病。

引用本文:

钟丽；张戈. 右旋糖酐铁联合促红细胞生成素对妊娠期缺铁性贫血患者网织红细胞、铁调素-25水平的影响[J]. 中国当代医药, 2022, 29(27): 104-107.
ZHONG Li ；ZHANG Ge. Effect of Iron Dextran combined with erythropoietin on the levels of reticulocyte and hepcidin-25 in patients with iron deficiency anemia during pregnancy. 中国当代医药, 2022, 29(27): 104-107.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2022/V29/I27/104

[1]	尹璐瑶，梁旭东，武海荣，等.妊娠期缺铁性贫血的影响因素及琥珀酸亚铁片的治疗效果研究[J].现代生物医学进展，2021，21（9）：1772-1776.
[2]	黄卉.妊娠期缺铁性贫血对妊娠结局的影响及临床防治[J].中国药物与临床，2018，18（10）：1807-1809.
[3]	周容，徐岚，马玉燕，等.蛋白琥珀酸铁口服溶液治疗妊娠期缺铁性贫血疗效研究[J].中国实用妇科与产科杂志，2019，35（3）：232-234.
[4]	杜林哲，朱余兵，刘赟心，等.重组人促红细胞生成素联合铁剂治疗围手术期贫血[J].药学与临床研究，2017，25（6）：537-538.
[5]	零庆珍，龙凌云，黄秀娟，等.重组人促红细胞生成素联合铁剂治疗早产儿贫血的临床疗效[J].临床合理用药杂志，2018，11（36）：73-74.
[6]	李杰，徐伯兰.多糖铁复合物胶囊治疗妊娠期缺铁性贫血的疗效观察[J].现代药物与临床，2021，36（12）：2627-2631.
[7]	汪霞，陶冶，王克涛，等.蛋白琥珀酸铁联合生血宁治疗妊娠期缺铁性贫血效果[J].临床军医杂志，2019，47（9）：947-951.
[8]	赵娜.妊娠期缺铁性贫血发病的危险因素及对妊娠结局的影响[J].中国妇幼保健，2021，36（5）：1139-1141.
[9]	史生辉，李燕君，李生有，等.健脾生血片与右旋糖酐铁片治疗妊娠期缺铁性贫血的临床比较研究[J].世界中医药，2018，13（9）：2241-2243.
[10]	吴进，李慧，肖凯，等.右旋糖酐铁联合EPO 治疗妊娠期缺铁性贫血疗效及其对RET，Hepcidin-25 水平的影响[J].疑难病杂志，2021，20（5）：492-496.
[11]	齐亮，邱辉，付玉.血清铁调素-25 水平对妊娠期缺铁性贫血诊治的意义及与围产结局的关系[J].中国临床研究，2019，32（11）：1471-1475.
[12]	常园园，范秋灵.Erythroferrone-铁调素轴在肾性贫血中的研究进展[J].中国临床研究，2017，30（2）：268-271.
[13]	洪秀珍.乐清地区妊娠中晚期妇女血清铁蛋白水平，孕妇缺铁性贫血患病情况及其对妊娠结局的影响[J].中国妇幼保健，2020，35（6）：995-998.
[14]	杨柯，郭晓宇，吴涛，等.西北高原汉族健康成人网织红细胞计数参考值的建立及其在贫血诊断中的应用[J].西北国防医学杂志，2021，42（3）：133-136.
[15]	栗杰，秘营昌，邱录贵，等.重组人促红细胞生成素联合蔗糖铁治疗消化道肿瘤相关性贫血临床效果研究[J].临床军医杂志，2021，49（7）：824-827.
[16]	陈会欣，王顺.重组人促红细胞生成素联合铁剂治疗术后贫血的疗效分析[J].中国输血杂志，2020，33（7）：660-663.
[17]	关文畅，白枫，李辉.重组人促红细胞生成素联合蔗糖铁治疗子宫肌瘤剔除术后中度贫血的临床效果[J].中国当代医药，2020，27（4）：143-145.